Amalgamated Bank acquired a new stake in Regenxbio Inc (NASDAQ:RGNX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,966 shares of the biotechnology company’s stock, valued at approximately $208,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGNX. Berman Capital Advisors LLC purchased a new position in Regenxbio during the fourth quarter worth $33,000. NumerixS Investment Technologies Inc acquired a new position in Regenxbio in the fourth quarter valued at $50,000. Riverhead Capital Management LLC boosted its holdings in Regenxbio by 137.5% in the third quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 1,100 shares during the last quarter. LS Investment Advisors LLC boosted its holdings in Regenxbio by 63.1% in the fourth quarter. LS Investment Advisors LLC now owns 2,260 shares of the biotechnology company’s stock valued at $95,000 after acquiring an additional 874 shares during the last quarter. Finally, Meeder Asset Management Inc. boosted its holdings in Regenxbio by 31.7% in the fourth quarter. Meeder Asset Management Inc. now owns 2,578 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 621 shares during the last quarter. 82.64% of the stock is owned by hedge funds and other institutional investors.
RGNX has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Regenxbio from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a report on Friday, February 22nd. ValuEngine upgraded Regenxbio from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Finally, BidaskClub upgraded Regenxbio from a “sell” rating to a “hold” rating in a report on Wednesday, March 6th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $78.72.
Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.04). The business had revenue of $0.88 million during the quarter. Regenxbio had a return on equity of 22.33% and a net margin of 45.74%. On average, research analysts anticipate that Regenxbio Inc will post -3.17 earnings per share for the current year.
In other news, CEO Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $47.29, for a total transaction of $709,350.00. Following the completion of the transaction, the chief executive officer now directly owns 261,000 shares in the company, valued at $12,342,690. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Olivier Danos sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $52.66, for a total value of $105,320.00. Following the transaction, the insider now owns 8,500 shares of the company’s stock, valued at $447,610. The disclosure for this sale can be found here. Over the last three months, insiders sold 70,368 shares of company stock valued at $3,793,446. 13.80% of the stock is owned by corporate insiders.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Recommended Story: What is a put option?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.